Standard

Serial Llama Immunization with Various SARS-CoV-2 RBD Variants Induces Broad Spectrum Virus-Neutralizing Nanobodies. / Solodkov, Pavel P.; Najakshin, Alexander M.; Chikaev, Nikolai A. et al.

In: Vaccines, Vol. 12, No. 2, 129, 02.2024.

Research output: Contribution to journal › Article › peer-review

Harvard

Solodkov, PP, Najakshin, AM, Chikaev, NA, Kulemzin, SV, Mechetina, LV, Baranov, KO, Guselnikov, SV, Gorchakov, AA, Belovezhets, TN, Chikaev, AN, Volkova, OY, Markhaev, AG, Kononova, YV, Alekseev, AY, Gulyaeva, MA, Shestopalov, AM & Taranin, AV 2024, 'Serial Llama Immunization with Various SARS-CoV-2 RBD Variants Induces Broad Spectrum Virus-Neutralizing Nanobodies', Vaccines, vol. 12, no. 2, 129. https://doi.org/10.3390/vaccines12020129

APA

Solodkov, P. P., Najakshin, A. M., Chikaev, N. A., Kulemzin, S. V., Mechetina, L. V., Baranov, K. O., Guselnikov, S. V., Gorchakov, A. A., Belovezhets, T. N., Chikaev, A. N., Volkova, O. Y., Markhaev, A. G., Kononova, Y. V., Alekseev, A. Y., Gulyaeva, M. A., Shestopalov, A. M., & Taranin, A. V. (2024). Serial Llama Immunization with Various SARS-CoV-2 RBD Variants Induces Broad Spectrum Virus-Neutralizing Nanobodies. Vaccines, 12(2), [129]. https://doi.org/10.3390/vaccines12020129

Vancouver

Solodkov PP, Najakshin AM, Chikaev NA, Kulemzin SV, Mechetina LV, Baranov KO et al. Serial Llama Immunization with Various SARS-CoV-2 RBD Variants Induces Broad Spectrum Virus-Neutralizing Nanobodies. Vaccines. 2024 Feb;12(2):129. doi: 10.3390/vaccines12020129

Author

Solodkov, Pavel P. ; Najakshin, Alexander M. ; Chikaev, Nikolai A. et al. / Serial Llama Immunization with Various SARS-CoV-2 RBD Variants Induces Broad Spectrum Virus-Neutralizing Nanobodies. In: Vaccines. 2024 ; Vol. 12, No. 2.

BibTeX

@article{aba20a2d6c174896ba7e1b0ba7201675,
title = "Serial Llama Immunization with Various SARS-CoV-2 RBD Variants Induces Broad Spectrum Virus-Neutralizing Nanobodies",
abstract = "The emergence of SARS-CoV-2 mutant variants has posed a significant challenge to both the prevention and treatment of COVID-19 with anti-coronaviral neutralizing antibodies. The latest viral variants demonstrate pronounced resistance to the vast majority of human monoclonal antibodies raised against the ancestral Wuhan variant. Less is known about the susceptibility of the evolved virus to camelid nanobodies developed at the start of the pandemic. In this study, we compared nanobody repertoires raised in the same llama after immunization with Wuhan{\textquoteright}s RBD variant and after subsequent serial immunization with a variety of RBD variants, including that of SARS-CoV-1. We show that initial immunization induced highly potent nanobodies, which efficiently protected Syrian hamsters from infection with the ancestral Wuhan virus. These nanobodies, however, mostly lacked the activity against SARS-CoV-2 omicron-pseudotyped viruses. In contrast, serial immunization with different RBD variants resulted in the generation of nanobodies demonstrating a higher degree of somatic mutagenesis and a broad range of neutralization. Four nanobodies recognizing distinct epitopes were shown to potently neutralize a spectrum of omicron variants, including those of the XBB sublineage. Our data show that nanobodies broadly neutralizing SARS-CoV-2 variants may be readily induced by a serial variant RBD immunization.",
keywords = "COVID-19, SARS-CoV-2, antiviral nanobody, broadly neutralizing antibody, coronavirus variants, single-domain antibody, viral evasion",
author = "Solodkov, {Pavel P.} and Najakshin, {Alexander M.} and Chikaev, {Nikolai A.} and Kulemzin, {Sergey V.} and Mechetina, {Ludmila V.} and Baranov, {Konstantin O.} and Guselnikov, {Sergey V.} and Gorchakov, {Andrey A.} and Belovezhets, {Tatyana N.} and Chikaev, {Anton N.} and Volkova, {Olga Y.} and Markhaev, {Alexander G.} and Kononova, {Yulia V.} and Alekseev, {Alexander Y.} and Gulyaeva, {Marina A.} and Shestopalov, {Alexander M.} and Taranin, {Alexander V.}",
note = "This research was funded by the Ministry of Science and Higher Education of the Russian Federation (Agreement No. 075-15-2021-1086, contract No. RF----193021X0015, 15.ИП.21.0015).",
year = "2024",
month = feb,
doi = "10.3390/vaccines12020129",
language = "English",
volume = "12",
journal = "Vaccines",
issn = "2076-393X",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "2",

}

RIS

TY - JOUR

T1 - Serial Llama Immunization with Various SARS-CoV-2 RBD Variants Induces Broad Spectrum Virus-Neutralizing Nanobodies

AU - Solodkov, Pavel P.

AU - Najakshin, Alexander M.

AU - Chikaev, Nikolai A.

AU - Kulemzin, Sergey V.

AU - Mechetina, Ludmila V.

AU - Baranov, Konstantin O.

AU - Guselnikov, Sergey V.

AU - Gorchakov, Andrey A.

AU - Belovezhets, Tatyana N.

AU - Chikaev, Anton N.

AU - Volkova, Olga Y.

AU - Markhaev, Alexander G.

AU - Kononova, Yulia V.

AU - Alekseev, Alexander Y.

AU - Gulyaeva, Marina A.

AU - Shestopalov, Alexander M.

AU - Taranin, Alexander V.

N1 - This research was funded by the Ministry of Science and Higher Education of the Russian Federation (Agreement No. 075-15-2021-1086, contract No. RF----193021X0015, 15.ИП.21.0015).

PY - 2024/2

Y1 - 2024/2

N2 - The emergence of SARS-CoV-2 mutant variants has posed a significant challenge to both the prevention and treatment of COVID-19 with anti-coronaviral neutralizing antibodies. The latest viral variants demonstrate pronounced resistance to the vast majority of human monoclonal antibodies raised against the ancestral Wuhan variant. Less is known about the susceptibility of the evolved virus to camelid nanobodies developed at the start of the pandemic. In this study, we compared nanobody repertoires raised in the same llama after immunization with Wuhan’s RBD variant and after subsequent serial immunization with a variety of RBD variants, including that of SARS-CoV-1. We show that initial immunization induced highly potent nanobodies, which efficiently protected Syrian hamsters from infection with the ancestral Wuhan virus. These nanobodies, however, mostly lacked the activity against SARS-CoV-2 omicron-pseudotyped viruses. In contrast, serial immunization with different RBD variants resulted in the generation of nanobodies demonstrating a higher degree of somatic mutagenesis and a broad range of neutralization. Four nanobodies recognizing distinct epitopes were shown to potently neutralize a spectrum of omicron variants, including those of the XBB sublineage. Our data show that nanobodies broadly neutralizing SARS-CoV-2 variants may be readily induced by a serial variant RBD immunization.

AB - The emergence of SARS-CoV-2 mutant variants has posed a significant challenge to both the prevention and treatment of COVID-19 with anti-coronaviral neutralizing antibodies. The latest viral variants demonstrate pronounced resistance to the vast majority of human monoclonal antibodies raised against the ancestral Wuhan variant. Less is known about the susceptibility of the evolved virus to camelid nanobodies developed at the start of the pandemic. In this study, we compared nanobody repertoires raised in the same llama after immunization with Wuhan’s RBD variant and after subsequent serial immunization with a variety of RBD variants, including that of SARS-CoV-1. We show that initial immunization induced highly potent nanobodies, which efficiently protected Syrian hamsters from infection with the ancestral Wuhan virus. These nanobodies, however, mostly lacked the activity against SARS-CoV-2 omicron-pseudotyped viruses. In contrast, serial immunization with different RBD variants resulted in the generation of nanobodies demonstrating a higher degree of somatic mutagenesis and a broad range of neutralization. Four nanobodies recognizing distinct epitopes were shown to potently neutralize a spectrum of omicron variants, including those of the XBB sublineage. Our data show that nanobodies broadly neutralizing SARS-CoV-2 variants may be readily induced by a serial variant RBD immunization.

KW - COVID-19

KW - SARS-CoV-2

KW - antiviral nanobody

KW - broadly neutralizing antibody

KW - coronavirus variants

KW - single-domain antibody

KW - viral evasion

UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85185666872&origin=inward&txGid=f0cc56d191fcddac110ac0774c648e1f

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:001172605500001

UR - https://www.mendeley.com/catalogue/4289d137-2325-36d1-910e-9395ca8c26f1/

U2 - 10.3390/vaccines12020129

DO - 10.3390/vaccines12020129

M3 - Article

C2 - 38400113

VL - 12

JO - Vaccines

JF - Vaccines

SN - 2076-393X

IS - 2

M1 - 129

ER -

ID: 61201187